EA201201617A1 - Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы - Google Patents

Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы

Info

Publication number
EA201201617A1
EA201201617A1 EA201201617A EA201201617A EA201201617A1 EA 201201617 A1 EA201201617 A1 EA 201201617A1 EA 201201617 A EA201201617 A EA 201201617A EA 201201617 A EA201201617 A EA 201201617A EA 201201617 A1 EA201201617 A1 EA 201201617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucokinase activator
combination
compositions containing
activator
metformin
Prior art date
Application number
EA201201617A
Other languages
English (en)
Other versions
EA032085B1 (ru
Inventor
Эднан М.М. Мджалли
Мария Кармен Валькарсе-Лопес
Original Assignee
Транстех Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Транстех Фарма, Инк. filed Critical Транстех Фарма, Инк.
Publication of EA201201617A1 publication Critical patent/EA201201617A1/ru
Publication of EA032085B1 publication Critical patent/EA032085B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Изобретение касается применения активатора глюкокиназы в комбинации с метформином в медицине. Варианты применения включают лечение диабета 2 типа, снижение уровня глюкозы, улучшение чувствительности к инсулину, увеличение фосфорилирования глюкозы и улучшение терапевтической эффективности метформина. Кроме того, изобретение касается фармацевтических композиций, содержащих активатор GK и метформин. Изобретение также касается соли, образованной метформином и активатором GK.
EA201201617A 2010-05-26 2011-05-24 Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы EA032085B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34855410P 2010-05-26 2010-05-26
PCT/US2011/037752 WO2011149945A1 (en) 2010-05-26 2011-05-24 Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator

Publications (2)

Publication Number Publication Date
EA201201617A1 true EA201201617A1 (ru) 2013-04-30
EA032085B1 EA032085B1 (ru) 2019-04-30

Family

ID=45004334

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201617A EA032085B1 (ru) 2010-05-26 2011-05-24 Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы

Country Status (30)

Country Link
US (4) US9359313B2 (ru)
EP (1) EP2576524B1 (ru)
JP (1) JP5902676B2 (ru)
KR (2) KR101860120B1 (ru)
CN (1) CN102906077B (ru)
AU (1) AU2011258460B2 (ru)
BR (1) BR112012029844A2 (ru)
CA (1) CA2799591C (ru)
CO (1) CO6640324A2 (ru)
CY (1) CY1119850T1 (ru)
DK (1) DK2576524T3 (ru)
EA (1) EA032085B1 (ru)
ES (1) ES2655396T3 (ru)
HK (1) HK1181044A1 (ru)
HR (1) HRP20180113T1 (ru)
HU (1) HUE036009T2 (ru)
IL (1) IL223137A0 (ru)
LT (1) LT2576524T (ru)
ME (1) ME03007B (ru)
MX (1) MX347372B (ru)
NO (1) NO2576524T3 (ru)
NZ (1) NZ603614A (ru)
PE (1) PE20130275A1 (ru)
PL (1) PL2576524T3 (ru)
PT (1) PT2576524T (ru)
RS (1) RS56761B1 (ru)
SG (1) SG185660A1 (ru)
SI (1) SI2576524T1 (ru)
TW (1) TWI508723B (ru)
WO (1) WO2011149945A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03007B (me) * 2010-05-26 2018-10-20 Vtv Therapeutics Llc Upotreba metformina u kombinaciji sa akтivatorom glukokinaze i kompozicije које sadrze metformin i aktivator glukoкinaze
WO2013173417A2 (en) * 2012-05-17 2013-11-21 Transtech Pharma, Inc. Glucokinase activator compositions for the treatment of diabetes
MX2015011110A (es) * 2013-03-04 2015-10-29 Vtv Therapeutics Llc Composiciones solidas que comprenden un activador de glucoquinasa y metodos para elaborar y utilizar las mismas.
CA2903433A1 (en) * 2013-03-04 2014-09-12 Vtv Therapeutics Llc Stable glucokinase activator compositions
CN117069622A (zh) * 2016-11-09 2023-11-17 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
SG11202011886TA (en) * 2018-05-31 2020-12-30 Hua Medicine Shanghai Ltd PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
EP4161639A4 (en) * 2020-06-08 2024-01-17 vTv Therapeutics LLC CRYSTALLINE FORMS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO!-3-THIAZOLE-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF
EP4161640A4 (en) * 2020-06-08 2024-01-17 vTv Therapeutics LLC SALTS OR COCRYSTALS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO)-THIAZOLE-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF
CN115073330A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 二甲双胍肉桂酸盐及制备方法和其组合物与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) * 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (ru) 1973-09-19 1977-01-28 Semb
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
CA2744893A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
ITRM20030053A1 (it) * 2003-02-10 2004-08-11 Sigma Tau Ind Farmaceuti Associazione di farmaci antidiabetici.
AU2003269484A1 (en) 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
CA2551324C (en) 2004-01-06 2012-11-27 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
JP2008515818A (ja) * 2004-10-07 2008-05-15 ステム セル セラピューティクス コーポレイション 妊娠に関連する化合物の投与による多能性幹細胞の増殖の刺激
US7999114B2 (en) * 2005-07-08 2011-08-16 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
US7582769B2 (en) * 2005-07-08 2009-09-01 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
AU2006268589B2 (en) * 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
EP2118083A1 (en) * 2007-01-09 2009-11-18 Novo Nordisk A/S Urea glucokinase activators
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators
KR101190957B1 (ko) * 2009-08-25 2012-10-15 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
ME03007B (me) * 2010-05-26 2018-10-20 Vtv Therapeutics Llc Upotreba metformina u kombinaciji sa akтivatorom glukokinaze i kompozicije које sadrze metformin i aktivator glukoкinaze
WO2013173417A2 (en) 2012-05-17 2013-11-21 Transtech Pharma, Inc. Glucokinase activator compositions for the treatment of diabetes
CA2903433A1 (en) 2013-03-04 2014-09-12 Vtv Therapeutics Llc Stable glucokinase activator compositions
MX2015011110A (es) 2013-03-04 2015-10-29 Vtv Therapeutics Llc Composiciones solidas que comprenden un activador de glucoquinasa y metodos para elaborar y utilizar las mismas.

Also Published As

Publication number Publication date
PL2576524T3 (pl) 2018-03-30
ES2655396T3 (es) 2018-02-19
ME03007B (me) 2018-10-20
CA2799591C (en) 2019-06-11
JP2013526608A (ja) 2013-06-24
SG185660A1 (en) 2012-12-28
NO2576524T3 (ru) 2018-03-24
TWI508723B (zh) 2015-11-21
EP2576524A4 (en) 2014-03-05
EA032085B1 (ru) 2019-04-30
JP5902676B2 (ja) 2016-04-13
MX347372B (es) 2017-04-25
NZ603614A (en) 2014-10-31
RS56761B1 (sr) 2018-04-30
US10363244B2 (en) 2019-07-30
CY1119850T1 (el) 2018-06-27
US20180344706A1 (en) 2018-12-06
TW201201791A (en) 2012-01-16
DK2576524T3 (en) 2018-01-22
CO6640324A2 (es) 2013-03-22
KR20130109015A (ko) 2013-10-07
CN102906077B (zh) 2015-03-04
WO2011149945A1 (en) 2011-12-01
HUE036009T2 (hu) 2018-06-28
EP2576524A1 (en) 2013-04-10
LT2576524T (lt) 2017-12-27
US10064846B2 (en) 2018-09-04
IL223137A0 (en) 2013-02-03
PT2576524T (pt) 2017-11-17
US20110313007A1 (en) 2011-12-22
KR101878252B1 (ko) 2018-07-13
US20160184277A1 (en) 2016-06-30
US9855251B2 (en) 2018-01-02
US9359313B2 (en) 2016-06-07
PE20130275A1 (es) 2013-03-17
BR112012029844A2 (pt) 2015-10-13
EP2576524B1 (en) 2017-10-25
HK1181044A1 (en) 2013-11-01
KR20180028539A (ko) 2018-03-16
US20170354647A1 (en) 2017-12-14
MX2012013617A (es) 2013-03-20
CN102906077A (zh) 2013-01-30
AU2011258460A1 (en) 2013-01-10
CA2799591A1 (en) 2011-12-01
HRP20180113T1 (hr) 2018-02-23
AU2011258460B2 (en) 2015-02-19
SI2576524T1 (en) 2018-01-31
KR101860120B1 (ko) 2018-05-23

Similar Documents

Publication Publication Date Title
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
BR112012029395A2 (pt) lactamas piperdinil-substituídas como moduladores de gpr119
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201991014A1 (ru) Лечение диабета
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
EA201200952A1 (ru) Производные пиразина и их применение для лечения неврологических нарушений
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
EA201170349A1 (ru) Модуляторы mif
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
EA201590058A1 (ru) Аналоги глюкагона
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BR112014015630A2 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas
EA201201623A1 (ru) Лечение диабета 2 типа
PH12015501931A1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU